Previous pageTable of contents

REFERENCES

  1. R. Lowy, B. M.Willumsen et al., “Function and regulation of RAS”, Ann. Rev. Biochem., 62 851-891, 1993.
  2. R. Schaffer, R. Kim et al., “Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans”, Science, 245 379-385, 1989.
  3. L. Moores, M. D. Schaber et al., “Sequence dependence of protein isoprenylation”, J. Biol. Chem, 266 14603-14610, 1991.
  4. J. Chen, D. A. Andress et al., “cDNA cloning and expression of the peptide binding beta subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1”, Cell, 66 327-334, 1991.
  5. J. Chen, D. A. Andress et al., “Cloning and espression of a cDNA encoding the alpha subunit of rat p21ras farnesyltransferase”, Proc. Nat. Acad. Sci. USA, 88 11368-11372, 1991.
  6. Reiss, M. L. Brown et al., “Bivalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain a zinc metallo-enzime”, J. Biol. Chem., 267 6403-6408, 1992.
  7. W. Fu, J. F. Moomaw et al., “Identification of a cysteine residue essential for activity of protein farnesyltransferase”, J. Biol. Chem., 271 28541-28548, 1996.
  8. Reiss, M. C. Seabra et al., “Non identical subunit of p21 HRAS farnesyltransferase: peptide binding and FPP carrier functions”, J. Biol Chem., 266 10672-10677, 1991.
  9. B. Gibbs, D. L. Pompliano et al. “A selective inhibition of farnesyl protein transferase blocks RAS processing in vivo”, J. Biol. Chem, 268 7617-6220, 1993.
  10. G. L. James, J L. Goldstein et al., “Benzodiazepin peptido mimetics: potent inhibitors of RAS farnesylation in animal cells”, Science, 260 1937-1942, 1993.
  11. P. J. Sidebottom, R. M. Highcock et al., “The Squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma “, J. Antibiotics, 45 639-658, 1992.
  12. C. Liu, M. Barbacid et al., “10'-Desmethoxystreptonigrin, a novel analog of streptonigrin”, J. Antibiotics, 45 454-457, 1992.
  13. B. Singh, E. T. Jones et al., “Fusidienol: a novel inhibitor of RAS farnesyl-protein transferase from Fusidium Griseum”, Tetrahedron Letters, 35 4963-4966, 1994.
  14. R. Bishop, R. Bond et al, “Novel tricyclic inhibitor of farnesyl-protein transferase: biochemical characterisation and inhibition of RAS modification in transfected cos-cells”, J. Biol. Chem., 270 30611-30618, 1995.
  15. Park, S. R. Boduluri et al., “Crystal structure of protein farnesyl transferase at 2.25 ┼ resolution”, Science, 275 1800-1805, 1997.
  16. Pedretti, A. M. Villa, L. Villa and G. Vistoli, “Interactions of some PGHS-2 selective inhibitors with the PGHS-1: an automated docking study by BioDock”, Il Farmaco, 52 487-491, 1997.
  17. Pedretti, A. M. Villa, L. Villa and G. Vistoli, “Modelling of the interactions of some inhibitors with the PGHS-1 by BioDock, a stochastic approach to the automated docking of ligands to biomacromolecules”, in Computer-Assisted Lead Finding and Optimization, Helvetica Chimica Acta Verlag, Basel, 1996.
  18. Pedretti, “Nuovo metodo per il docking automatico di ligandi con macromolecole a struttura 3D nota”, degree thesis, Milan University, 1995.
  19. Protein Data Bank, Chemistry Department, Brookhaven National Laboratory, USA.
  20. Quanta/CHARMm, MSI, Burlington, MA, USA.
  21. Leonard D. M., “RAS farnesyltransferase: a new therapeutic target”, Med. Chem., 40 2971-2990, 1997 and references cited herein.

 

HOW TO CONTACT THE AUTHORS

Please refer to Alessandro Pedretti

Istituto di Chimica Farmaceutica e Tossicologica
UniversitÓ di Milano
Viale Abruzzi, 42
I-20131 Milano - Italy
Tel. +39-02-29502230
Fax +39-02-29514197
E-Mail:
alex@indigo.farma.unimi.it